Brighten Optix Corporation (TPEX:6747)
198.50
0.00 (0.00%)
Oct 31, 2025, 2:31 PM CST
Brighten Optix Revenue
Brighten Optix had revenue of 161.77M TWD in the quarter ending June 30, 2025, a decrease of -3.04%. This brings the company's revenue in the last twelve months to 778.00M, up 3.56% year-over-year. In the year 2024, Brighten Optix had annual revenue of 766.93M with 2.63% growth.
Revenue (ttm)
778.00M
Revenue Growth
+3.56%
P/S Ratio
6.94
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 766.93M | 19.63M | 2.63% |
| Dec 31, 2023 | 747.30M | 3.03M | 0.41% |
| Dec 31, 2022 | 744.27M | 99.63M | 15.45% |
| Dec 31, 2021 | 644.64M | 103.58M | 19.14% |
| Dec 31, 2020 | 541.07M | 52.72M | 10.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| PharmaEssentia | 12.63B |
| Pegavision | 6.90B |
| Center Laboratories | 1.60B |
| Oneness Biotech | 112.57M |
| Polaris Group | 64.02M |
| Caliway Biopharmaceuticals | 44.83M |